Tenderwize
Back to tender search

Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2028 · 681 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

62 / 100

Complexity

58 / 100

Risk factors

The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...

Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Open House conclusion of pharmaceutical discount agreements under Section 130a(8) SGB V for Epoetin alfa and Epoetin zeta.
  • Nationwide supply/performance in Germany.
Show full summary

Open House procedure by Techniker Krankenkasse for non-exclusive discount agreements on pharmaceutical products for Epoetin alfa and Epoetin zeta (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with uniform conditions and no individual negotiation. The contract term is up to 24 months from 01/07/2026 to 30/06/2028. No contract value is stated in the provided data. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the procedure communication is via the TK portal communication area/email. Procurement documents are available online, but only the notice text was provided for analysis.

Risks

The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...

Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the relevant medicines.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the medicines and/or otherwise be entitled to place them on the market in its own name.

Award Criteria

Lot 1

Open House notice field only; award criteria not materially applicable.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta

Lot 1 concerns an Open House discount agreement for the medicinal products Epoetin alfa and Epoetin zeta. Scope is nationwide in Germany. The notice indicates open accession for all eligible pharmaceutical companies, no exclusivity, and no individual negotiation. The lot details come from structured data and notice text.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jun 2026 - Jun 2028

Category

Pharmaceutical products

Award Criteria

Open House notice field only; award criteria not materially applicable.

Deadline

Deadline Jun 30, 2028

Procurement Details

Publication date
07 May 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
317941-2026

Documents (1)

Similar tenders